GlobeNewswire: RadioMedix Inc. Contains the last 10 of 24 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:14:45ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/02/15/2608809/0/en/RadioMedix-Inc-Announces-the-Acquisition-of-its-225Ac-PSMA-I-T-program-a-Targeted-Alpha-Therapy-TAT-for-Metastatic-Castration-Resistant-Prostate-Cancer-by-Fusion-Pharmaceuticals-In.html?f=22&fvtc=4&fvtv=26952RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc.2023-02-15T14:00:00Z<![CDATA[Houston, TX, Feb. 15, 2023 (GLOBE NEWSWIRE) -- RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage radiopharmaceutical company announced the acquisition of it’s 225Ac-PSMA-I&T asset by Fusion Pharmaceuticals. Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. 225Ac-PSMA-I&T is currently being evaluated under a phase 2 physician-sponsored investigational new drug (IND) under the acronym of TATCIST trial. RadioMedix will also provide manufacturing support to Fusion for the TATCIST trial and first pivotal clinical trial to evaluate the safety and efficacy of 225Ac-PSMA-I&T for metastatic castration-resistant prostate cancer (mCRPC). As currently designed, the trial is expected to evaluate approximately 100 patients with four treatment cycles per patient, occurring every eight weeks. Patients are initially dosed at 100 kBq/kg.]]>https://www.globenewswire.com/news-release/2022/11/15/2555865/0/en/RadioMedix-and-Vect-Horus-announce-first-dosing-of-Glioblastoma-Multiforme-and-Pancreatic-ductal-adenocarcinoma-patients-with-68Ga-RMX-VH.html?f=22&fvtc=4&fvtv=26952RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH2022-11-15T11:00:00Z<![CDATA[Houston, TX, USA and Marseille, France, Nov. 15, 2022 (GLOBE NEWSWIRE) -- RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the diagnostic of Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC). This radiotracer will serve as a companion diagnostic for future Targeted Alpha Therapy (TAT) for these cancers. 68Ga-RMX-VH is a positron-emitting tomography (PET) agent that targets the Low-Density Lipoprotein Receptor (LDLR) overexpressed in some solid tumors such as GBM and PDAC. The objective of this exploratory study is to evaluate the safety, dosimetry, and bio-distribution of 68Ga-RMX-VH in patients with solid tumors. GBM is the most common malignant primary brain tumor in adults and is a serious and life-threatening disease. PDAC is one of the most chemo-resistant and radio-resistant types of cancers due to the dense pancreatic connective tissue and the diversity of genetic mutations. RadioMedix and Vect-Horus have already signed a co-development and a licensing agreement. Both parties will share the costs of development until Phase 1 for diagnostic and radiotherapy. RadioMedix is leading the clinical development and future commercialization.]]>https://www.globenewswire.com/news-release/2022/10/07/2530586/0/en/RadioMedix-announces-a-40-million-Series-A-financing-for-the-advancement-of-novel-Targeted-Alpha-Therapy-platform-and-diagnostic-companion-radiopharmaceuticals-to-address-unmet-nee.html?f=22&fvtc=4&fvtv=26952RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic companion radiopharmaceuticals to address unmet needs in oncology; Michael Lee-Chin appointed to the board of the company2022-10-07T22:11:34Z<![CDATA[HOUSTON and BURLINGTON, Ontario, Oct. 07, 2022 (GLOBE NEWSWIRE) -- RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage biotechnology company announced an agreement with an entity related to Portland Investment Counsel Inc. (“Portland”) involving an equity investment of $40 million Series A funding round. RadioMedix is committed to the advancement of a targeted alpha therapy (TAT) pipeline and diagnostic companion radiopharmaceuticals for rare and aggressive cancers.]]>https://www.globenewswire.com/news-release/2022/01/03/2360157/0/en/Radiomedix-and-Orano-Med-Announce-the-Initiation-of-the-Phase-II-Multi-Center-Clinical-Trial-of-Alphamedix-for-Targeted-Alpha-Emitter-Therapy-of-Neuroendocrine-Cancers.html?f=22&fvtc=4&fvtv=26952Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers 2022-01-03T16:00:00Z<![CDATA[Houston, TX and Plano, TX, Jan. 03, 2022 (GLOBE NEWSWIRE) -- RadioMedix and Orano Med are pleased to announce the initiation of the Phase II clinical trial of AlphaMedix™ with the treatment of the first patient on December 21st, 2021. This trial will evaluate the safety and effectiveness of 212Pb-DOTAMTATE (AlphaMedix™) in Peptide Receptor Radionuclide Therapy (PRRT) of naive patients with somatostatin receptor-expressing neuroendocrine tumors (NET).]]>https://www.globenewswire.com/news-release/2021/11/18/2337872/0/en/RADIOMEDIX-AWARDED-2-0-M-NCI-SBIR-DIRECT-TO-PHASE-II-GRANT-TO-DEVELOP-DRUG-FOR-TARGETED-ALPHA-EMITTER-THERAPY.html?f=22&fvtc=4&fvtv=26952RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY2021-11-18T22:00:00Z<![CDATA[Houston, TX, Nov. 18, 2021 (GLOBE NEWSWIRE) -- RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute at the US National Institutes of Health. The grant supports Phase I/II clinical development of innovative alpha-emitter labeled peptide, AlphaMedixTM, for therapy of somatostatin receptor-positive neuroendocrine tumors.]]>https://www.globenewswire.com/news-release/2021/08/04/2274430/0/en/Excel-Diagnostics-and-Nuclear-Oncology-Center-Announces-FDA-Authorization-of-IND-for-225Ac-PSMA-I-T-Targeted-Alpha-Therapy-for-Castration-Resistant-Prostate-Cancer.html?f=22&fvtc=4&fvtv=26952Excel Diagnostics and Nuclear Oncology Center Announces FDA Authorization of IND for 225Ac-PSMA I&T Targeted Alpha Therapy for Castration Resistant Prostate Cancer2021-08-04T11:00:00Z<![CDATA[Houston, TX, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Excel Diagnostics and Nuclear Oncology Center (EDNOC), a premier Diagnostic Imaging and Radioligand Therapy center in Houston, Texas announces approval of its physicians sponsored Investigational New Drug (IND) application for providing Targeted Alpha Therapy (TAT) with 225Ac-PSMA I&T for metastatic Castration-Resistant Prostate Cancer (mCRPC). “We are glad to be able to make this game-changing drug available to our patients suffering from mCRPC. Excel Diagnostics and Nuclear Oncology Center has been a pioneer in bringing new targeted Radioligand Therapies such as Lu-177 DOTATATE, and Lu-177 PSMA to serve our patients in the United States. The addition of 225Ac-PSMA I&T is in continuation of our mission to address unmet needs in the field of Nuclear Oncology” said Dr. Ebrahim Delpassand, Chairman and Medical Director of EDNOC and Co-Principal Investigator of the trial. “PSMA is an established prostate cancer target. Highly encouraging results have been reported by using Targeted Alpha Therapy (TAT) Radiopharmaceuticals in conditions such as neuroendocrine, prostate, or hematological malignancies. These breakthroughs have brought a significant amount of hope to our patients suffering from different types of advanced cancers.” said Dr. Rodolfo Nuñez, Director of Nuclear Medicine Department at EDNOC and Co-Principal Investigator of the trial. “We are pleased to be able to facilitate the availability of 225Ac-PSMA I&T by manufacturing this drug at RadioMedix. We firmly believe that the menu of targeted Radioligand Therapies will only increase in the future. RadioMedix with its wide range of capabilities, from drug discovery to scale-up commercial manufacturing, is ready to meet this challenge” said Dr. David Ranganathan, Director of CMC and Regulatory affairs at RadioMedix.]]>https://www.globenewswire.com/news-release/2021/01/04/2152803/0/en/RadioMedix-wins-2020-TechConnect-Innovation-Award-and-pitched-at-Virtual-TechConnect-Business-Summit.html?f=22&fvtc=4&fvtv=26952RadioMedix wins 2020 TechConnect Innovation Award and pitched at Virtual TechConnect Business Summit2021-01-04T16:00:00Z<![CDATA[Houston (TX), Jan. 04, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. Houston-based clinical-stage radiopharmaceutical company is proud to announce that the company was selected for the 2020 TechConnect Innovation Award. The annual TechConnect Business Innovation Awards program recognizes the top 15% of submitted technologies as ranked by the selection committee in multiple categories from the Energy, Nanomaterials, Health and Medicine, AI, Robotics, and others. The Summit is co-organized by SBIR/STTR Innovation Program and co-located with Defense Innovation Summit.]]>2020 TechConnect AwardtechConnect award logohttps://www.globenewswire.com/news-release/2020/10/13/2107285/0/en/RadioMedix-appointed-Dr-Ferey-Faridian-as-new-member-of-the-Board-of-Director.html?f=22&fvtc=4&fvtv=26952RadioMedix appointed Dr.Ferey Faridian as new member of the Board of Director2020-10-13T09:00:00Z<![CDATA[Houston, TX, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Radiomedix a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer, announced the appointment of Dr. Ferey Faridian as a member of its Board of Directors.]]>https://www.globenewswire.com/news-release/2020/02/25/1989642/0/en/Excel-Nuclear-Oncology-Center-initiates-the-first-Lu-177-DOTATOC-PRRT-clinical-trial-for-the-PUT-Neuroendocrine-Tumors-in-U-S.html?f=22&fvtc=4&fvtv=26952Excel Nuclear Oncology Center initiates the first Lu-177 DOTATOC PRRT clinical trial for the PUT-Neuroendocrine Tumors, in U.S.2020-02-25T03:00:00Z<![CDATA[Houston, TX, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Excel Diagnostics and Nuclear Oncology Center (EDNOC) announced today that its physician sponsored Investigational New Drug (IND) application to evaluate safety and efficacy of Lu-177 DOTATOC in adult subjects with Somatostatin receptor (SSTR) expressing Pulmonary, pheochromocytoma, Paraganglioma, Unknown primary, and Thymus Neuroendocrine Tumors (PUT-NET), has received approval to proceed by USA Food and Drug Administration (FDA) and also charge authorization has been granted (IND#143631, NCT04276597). This IND is anticipated to start enrolling patients by early March 2020.]]>https://www.globenewswire.com/news-release/2020/02/10/1982599/0/en/RadioMedix-and-OncoBeta-announce-exclusive-distribution-agreement-for-W-Re-188-generators-in-U-S-and-Canada.html?f=22&fvtc=4&fvtv=26952RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada2020-02-10T21:00:00Z<![CDATA[Houston, TX, USA, and Garching, Germany, Feb. 10, 2020 (GLOBE NEWSWIRE) -- RadioMedix, and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of W/Re-188 generators in the U.S. and Canada.]]>OncoBeta® Tungsten (Wolfram)-188/Rhenium-188 (W/Re-188) GeneratorOncoBeta® Tungsten (Wolfram)-188/Rhenium-188 (W/Re-188) Generator